QMAC-DST for Rapid Detection of Drug Resistance in Pulmonary Tuberculosis Patients: A Multicenter Pre-Post Comparative Study
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q1Scopus Q1
- 저널
- JOURNAL OF CLINICAL MEDICINE13(10) · 2024
- 피인용
- Web of Science 0Scopus 0
- FWCI (Scopus)
- 0
- JCR IF
- JCR 2023 3
- ISSN
- 2077-0383
저자
- Kwak, Nakwon제1저자Seoul Natl Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Seoul 03080, South Korea
- Lee, SangyeopQuantaMatrix Inc, 131 Gasan digital 1 Ro, Seoul 08506, South Korea
- Kim, SuyeounQuantaMatrix Inc, 131 Gasan digital 1 Ro, Seoul 08506, South Korea
- Song, EunbeeQuantaMatrix Inc, 131 Gasan digital 1 Ro, Seoul 08506, South Korea
- Yim, Jae-JoonSeoul Natl Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, Seoul 03080, South Korea
- Shim, Tae SunUniv Ulsan, Asan Med Ctr, Coll Med, Dept Pulm & Crit Care Med, Seoul 05505, South Korea
- 전두수Pusan Natl Univ, Yangsan Hosp, Dept Internal Med, Yangsan 50612, South Korea
- Jhun, Byung WooSungkyunkwan Univ, Samsung Med Ctr, Dept Med,Sch Med, Div Pulm & Crit Care Med, Seoul 06351, South Korea
- Seok, Kwang-HyukKorean Inst TB, Dept Lab Med, Cheongju 28158, South Korea
- 김새롬Pusan Natl Univ Hosp, Dept Internal Med, 179 Gudeok Ro, Busan 49241, South Korea
- Kwon, Sunghoon교신저자QuantaMatrix Inc, 131 Gasan digital 1 Ro, Seoul 08506, South Korea
- 목정하교신저자Pusan Natl Univ, Sch Med, Dept Internal Med, Busan 49241, South Korea
초록
Background/Objectives: This study explores the impact of QMAC-DST, a rapid, fully automated phenotypic drug susceptibility test (pDST), on the treatment of tuberculosis (TB) patients. Methods: This pre–post comparative study, respectively, included pulmonary TB patients who began TB treatment between 1 December 2020 and 31 October 2021 (pre-period; pDST using the Löwenstein–Jensen (LJ) DST (M-kit DST)) and between 1 November 2021 and 30 September 2022 (post-period; pDST using the QMAC-DST) in five university-affiliated tertiary care hospitals in South Korea. We compared the turnaround times (TATs) of pDSTs and the time to appropriate treatment for patients whose anti-TB drugs were changed based on these tests between the groups. All patients were permitted to use molecular DSTs (mDSTs). Results: A total of 182 patients (135 in the M-kit DST group and 47 in the QMAC-DST group) were included. The median TAT was 36 days for M-kit DST (interquartile range (IQR), 30–39) and 12 days for QMAC-DST (IQR, 9–15), with the latter being significantly shorter (p < 0.001). Of the total patients, 10 (5.5%) changed their anti-TB drugs based on the mDST or pDST results after initiating TB treatment (8 in the M-kit DST group and 2 in the QMAC-DST group). In the M-kit DST group, three (37.5%) patients changed anti-TB drugs based on the pDST results. In the QMAC-DST group, all changes were due to mDST results; therefore, calculating the time to appropriate treatment for patients whose anti-TB drugs were changed based on pDST results was not feasible. In the QMAC-DST group, 46.8% of patients underwent the first-line line probe assay compared to 100.0% in the M-kit DST group (p < 0.001), indicating that rapid QMAC-DST results provide quicker assurance of the ongoing treatment by confirming susceptibility to the current anti-TB drugs. Conclusions: QMAC-DST delivers pDST results more rapidly than LJ-DST, ensuring faster confirmation for the current treatment regimen.
키워드
drug susceptibility testQMAC-DSTresistancetuberculosisMYCOBACTERIUM-TUBERCULOSISDIAGNOSIS
식별자
- Scopus EID
- 2-s2.0-85194237902
- WoS UID
- 001234862600001



로그인
연구물 목록으로